Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy

Patients with lymphoid malignancies are at a higher risk of coronavirus disease 2019 (COVID-19) infection due to their immunocompromised state and results in higher mortality rates in these patients. Anti-CD 20 therapy is one of the leading causes of immunosuppression that worsens in COVID-19 cases....

Descripción completa

Detalles Bibliográficos
Autores principales: Sahu, Tarun, Verma, Henu Kumar, Lvks, Bhaskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372783/
https://www.ncbi.nlm.nih.gov/pubmed/36159615
http://dx.doi.org/10.5501/wjv.v11.i4.204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372783/
https://www.ncbi.nlm.nih.gov/pubmed/36159615
http://dx.doi.org/10.5501/wjv.v11.i4.204

Ejemplares similares